# US 2005/0020680 A1 · Hydroxyfattysulfonic acid analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0020680 A1
- Document ID: US20050020680A1
- Status: Published application
- Kind: A1
- Application number: 10/489,204
- Filed: 2002-09-09
- Published: 2005-01-27
- Earliest claimed: 2001-09-14
- Inventors: John Falck; Noriyuki Miyata; Naoya Ono; Tomomichi Chonan; Hitomi Hirano; Yoshihisa Toda; Tohru Tanami; Shigeru Okuyama
- Web page: https://patentgrep.com/patent/US20050020680A1

## CPC

- C07D 257/04: Five-membered rings
- C07C 33/044: Alkynediols
- C07C 33/423: {containing only double bonds as unsaturation}
- C07C 33/426: {containing only triple bonds as unsaturation}
- C07C 59/42: containing hydroxy or O-metal groups
- C07C 59/46: containing rings other than six-membered aromatic rings
- C07C 59/60: the non-carboxylic part of the ether being unsaturated
- C07C 69/708: Ethers
- C07C 235/28: the carbon skeleton being acyclic and unsaturated
- C07C 255/15: containing cyano groups and singly-bound oxygen atoms bound to the same unsaturated acyclic carbon skeleton
- C07C 259/06: having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 309/10: with the oxygen atom of at least one of the etherified hydroxy groups further bound to an acyclic carbon atom
- C07C 309/20: of an acyclic unsaturated carbon skeleton
- C07C 309/23: of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
- C07C 309/24: of a carbon skeleton containing six-membered aromatic rings
- C07C 309/68: of a carbon skeleton substituted by singly-bound oxygen atoms
- C07C 311/17: to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 311/51: Y being a hydrogen or a carbon atom
- C07C 317/44: having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C 323/52: the carbon skeleton being acyclic and saturated
- C07C 323/66: containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
- C07D 277/34: Oxygen atoms
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

A hydroxyfattysulfonic acid analog represented by Formula (I): wherein X is an ethylene group, a vinylene group or an ethynylene group; Y is an ethylene group, a vinylene group, an ethynylene group, OCH2 or S(O)pCH2 wherein p is 0, 1 or 2; m is an integer of 1 to 5 inclusive; n is an integer of 0 to 4 inclusive; R1 is a C1-8 alkyl group, a C3-8 cycloalkyl group, a C1-4 alkyl group substituted with a C3-8 cycloalkyl group, a C1-4 alkyl group substituted with an aryl group or a C1-4 alkyl group substituted with an aryloxy group; R2 is a hydrogen atom or a methyl group; R1 and R2 together with the carbon atom to which they are attached may form a C3-8 cycloalkyl group; R3 is a hydrogen atom or a C2-8 acyl group; R4 is OR5 or NHR6, wherein R5 is a hydrogen atom, a C1-4 alkyl group, an alkali metal, an alkaline earth metal or an ammonium group and R6 is a hydrogen atom or a C1-4 alkyl group; or a pharmaceutically acceptable salt or a hydrate thereof. The compounds of the present invention are useful as an elastase release inhibitor.

## Claims

### Claim 1

A hydroxyfattysulfonic acid analog represented by Formula (I):
wherein
X is an ethylene group, a vinylene group or an ethynylene group; Y is an ethylene group, a vinylene group, an ethynylene group, OCH2 or S(O)pCH2, wherein p is 0, 1 or 2; m is an integer of 1 to 5 inclusive; n is an integer of 0 to 4 inclusive;
R1 is a C1-6 alkyl group, a C3-8 cycloalkyl group, a C1-4 alkyl group substituted with a C3-8 cycloalkyl group, a C1-4 alkyl group substituted with an aryl group or a C1-4 alkyl group substituted with an aryloxy group; R2 is a hydrogen atom or a methyl group; R1 and R2 together with the carbon atom to which they are attached may form a C3-8 cycloalkyl group; R3 is a hydrogen atom or a C2-8 acyl group; R4 is OR5 or NHR6, wherein R5 is a hydrogen atom, a C1-4 alkyl group, an alkali metal, an alkaline earth metal or an ammonium group and R6 is a hydrogen atom or a C1-4 alkyl group; or
a pharmaceutically acceptable salt or a hydrate thereof.

### Claim 2 (depends on 1)

The hydroxyfattysulfonic acid analog of Formula (I) according to claim 1 wherein X is a vinylene group or an ethynylene group, Y is an ethylene group, a vinylene group, an ethynylene group, OCH2 or SCH2, R1 is a C1-8 alkyl group or a C3-8 cycloalkyl group, R2 is a hydrogen atom or a methyl group, R3 is a hydrogen atom, R4 is OR5 group and the sum of m and n is an integer of from 4 to 8, or a pharmaceutically acceptable salt or the hydrate thereof.

### Claim 3 (depends on 1)

The hydroxyfattysulfonic analog of Formula (I) according to claim 1 wherein the compound is sodium (R)-(4Z, 13Z)-15-hydroxynonadeca-4,13-diene-1-sulfonate or sodium (R)-(Z)-15-hydroxynonadec-13-ene-1-sulfonate

### Claim 4

An elastease-inhibiting composition which comprises a hydroxyfattysulfonic acid analog represented by the Formula (I):
wherein
X is an ethylene group, a vinylene group or an ethynylene group; Y is an ethylene group, a vinylene group, an ethynylene group, OCH2 or S(O)pCH2, wherein p is 0, 1 or 2; m is an integer of 1 to 5 inclusive; n is an integer of 0 to 4 inclusive;
R1 is a C1-8 alkyl group, a C3-8 cycloalkyl group, a C1-4 alkyl group substituted with a C3-8 cycloalkyl group, a C1-4 alkyl group substituted with an aryl group or a C1-4 alkyl group substituted with an aryloxy group; R2 is a hydrogen atom or a methyl group; R1 and R2 together with the carbon atom to which they are attached may form a C3-8 cycloalkyl group; R3 is a hydrogen atom or a C2-8 acyl group; R4 is OR5 or NHR6, wherein R5 is a hydrogen atom, a C1-4 alkyl group, an alkali metal, an alkaline earth metal or an ammonium group and R6 is a hydrogen atom or a C1-4 alkyl group; or
a pharmaceutically acceptable salt or a hydrate thereof and a pharmaceutically acceptable carrier.
